BioCryst Pharmaceuticals Inc BCRX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1994-03-04 |
| Shares Out. | 254,160,000 |
| Website | biocryst.com/ ↗ |
| Phone | 13026365400 |
| Employees | 435 |
| Revenue | $156.4M |
| Gross Profit | $151.0M |
| Net Income | -$721.8M |
| Free Cash Flow | $310.4M |
| Total Assets | $465.1M |
| Total Liabilities | $1.02B |
| Equity | -$553.8M |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
BioCryst Pharmaceuticals Inc is a publicly traded company under the ticker symbol BCRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)